Please assess the completion status of the following clinical trial:

Trial Title: RA Denosumab on Bone Microstructure Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* with a diagnosis of RA according to the 2010 new 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria~* at an age over 18 years old~* have a lumbar spine, or total hip or distal radius T-score lower than -1.5 by DXA~* without severe deformity in metacarpophalangeal (MCP) joints which would influence the longitudinal assessment of HR-pQCT~* consent to receive alendronate if randomized to standard treatment group.~Exclusion Criteria:~* they have previous use of denosumab, teriparatide, alendronate or other anti-resorptive agents;~* they have a history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis or GI ulceration) or have experienced any previous adverse reaction to bisphosphonate therapy;~* they are receiving other bone-active drugs, such as hormonal replacement therapy, thyroxine, thiazide and diuretics;~* they have conditions affecting bone metabolism; contraindications to alendronate and denosumab (uncorrected hypocalcemia);~* they have unexplained hypocalcemia;~* they have severe renal impairment or serum creatinine level of \>200umol/L;~* they are pregnant or breastfeeding;~* they do not understand Chinese or are incompetent in giving consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: EXPERIMENTAL): Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
- Standard treatment (Type: ACTIVE_COMPARATOR): Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.

Based on this trial design, predict the completion outcome and termination type (if applicable).